Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Macquarie Group Limited, along with its controlled entities, has ceased to be a substantial holder in Australian Clinical Labs Limited. This change in substantial holding may impact the company’s shareholder structure and influence its market dynamics, although specific implications for stakeholders are not detailed in the release.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.60 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Average Trading Volume: 826,101
Technical Sentiment Signal: Sell
Current Market Cap: A$549.9M
Learn more about ACL stock on TipRanks’ Stock Analysis page.